Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Eribulin and Radiation for Retroperitoneal Liposarcoma
NCT03361436Phase 1Active, not recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Mar 2018
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eribulin in retroperitoneal liposarcoma (RLS), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Incidence of dose limiting toxicities at 42 days. Started Mar 2018; status: active, not recruiting.
02
Drugs
eribulin
03
Conditions
retroperitoneal liposarcoma (RLS)
Beyond the preview
Go deeper on NCT03361436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03361436.